The survival time of patients with pancreatic cancer combined with liver metastases is inconclusive, with a small sample study showing a median survival of only 4 months. Pancreatic cancer is a malignant tumor of the digestive tract with insidious onset, rapid progression, and extremely poor therapeutic effect and prognosis. Early symptoms of pancreatic cancer are not obvious, and when symptoms appear or diagnosis is confirmed, it is mostly in the middle or late stage, and the best time for treatment has been lost. Pancreatic cancer combined with liver metastasis indicates that the patient is already in the advanced stage, and the specific survival period of the patient varies from person to person, which is related to the stage of the disease (size, location, number, metastasis), the patient’s own situation, treatment effect and other factors. Domestic small sample study illustrates that the overall median survival time of patients with pancreatic cancer combined with liver metastasis is 4 months, and the survival rates of 6 months, 1 year and 2 years are 39.1%, 21.9% and 7.8% respectively. In conclusion, the survival of pancreatic cancer patients is influenced by a variety of factors, and the prognosis of advanced pancreatic cancer is poor. If pancreatic cancer is suspected or diagnosed, it is recommended to go to regular hospitals for comprehensive assessment of the condition, follow the doctor’s instructions to cooperate with the treatment, and choose the appropriate treatment plan to improve the patient’s prognosis, enhance the quality of life, and prolong the survival period.